Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration
The collaboration leverages Remix’s REMaster™ platform to discover novel drugs for a diverse range of target classes
Remix is eligible to receive up to $1 billion in milestone payments and royalties
Related news for (RHHBY)
- From Spider Silk to Skin Science: Innovation Threads Through Wall Street
- Power Hour Playbook: Biotech Booms, Pill Deals & Spider Silk Dreams
- Biotech Ignites: Rani’s $1B Chugai Deal Sparks Sector Rally, Kezar Pivots, and AI-Driven Drugmakers Eye New Highs
- Cancer Breakthroughs, Blockchain Bets, and Biotech Boldness
- Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates